Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc), EULAR 2021 Virtual Congress
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series, American College of Rheumatology Convergence 2020
Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress
Health Assessment Questionnaire Disability Index (HAQ-DI) and Patient Global Assessment of Health (PtGA) Correlate with Changes in Patient Reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress
Patient and Physician Opinion of Clinical Benefit at 3 Months in a Clinical Trial Correlate with Patient Reported Outcomes (PROs), 6th Systemic Sclerosis World E-Congress
Baseline European Patient Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum, a CB2 Agonist, in Diffuse Cutaneous Systemic Sclerosis, EULAR 2020
Safety and Efficacy of Lenabasum in a Phase 2 Randomized, Placebo-Controlled Trial in Adults with Systemic Sclerosis
Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis, ACR 2019
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis, ACR 2019
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects, IWRS 2019
Performance of American College of Rheumatology (ACR) Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score in Phase 2 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc), IWRS 2019
Performance of American College of Rheumatology (ACR) Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score in Phase 2 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSS), EULAR 2019 Annual Meeting
Performance of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial with Lenabasum, EULAR 2019 Annual Meeting
Safety and Efficacy of Lenabasum in an Open-label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis, EULAR 2019 Annual Meeting
Safety and Efficacy of Lenabasum (JBT-101) in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects, American College of Rheumatology Annual Meeting
Safety And Efficacy Of Lenabasum (JBT-101) In Diffuse Cutaneous Systemic Sclerosis Subjects Treated For One Year In An Open-Label Extension Of Trial JBT101-SSc-001, Annual European Congress of Rheumatology
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial, American College of Rheumatology Annual Meeting
Prospective Validation of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc), American College of Rheumatology Annual Meeting
Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in An Open-Label Extension of Trial JBT101-SSc-001, American College of Rheumatology Annual Meeting
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease A Randomized Clinical Trial
Long-term Safety and Efficacy of Lenabasum during 3 Years in an Open-Label Extension (OLE) of a Phase 2 Study of Lenabasum in Refractory Skin Disease in Dermatomyositis (DM), EULAR 2021 Virtual Congress
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE), American College of Rheumatology Convergence 2020
CB2 Receptor Distribution and Effects of Lenabasum in Dermatomyositis In Vitro, American College of Rheumatology Convergence 2020
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects, ACR 2019
Design of a Phase 3 Study of Lenabasum for the Treatment of Dermatomyositis, EULAR 2019 Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces CD4+ Cell Populations and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin, EULAR 2019 Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin- Predominant Dermatomyositis (DM) Subjects, EULAR 2019 Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open-Label Extension of Trial JBT101-DM-001, American College of Rheumatology Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin, American College of Rheumatology Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open Label Extension of Trial JBT101-DM-001, Annual European Congress of Rheumatology
A Phase 2 Study of Safety and Efficacy of Lenabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis, Annual European Congress of Rheumatology
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, Annual European Congress of Rheumatology
CB2 Agonist, Lenabasum, for the Treatment of Pulmonary Exacerbations in Cystic Fibrosis, North American Cystic Fibrosis Conference 2020
Patient Demographics and Baseline Disease Characteristics in a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Lenabasum, a Selective Cannabinoid Receptor Type 2 Agonist, in Cystic Fibrosis, Journal of Cystic Fibrosis
Anti-Inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages from Cystic Fibrosis, Journal of Cystic Fibrosis
Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis, Frontiers in Pharmacology
Lenabasum Reduces LPS-induced Inflammation in Airway Macrophages from Human Cystic Fibrosis Lungs, North American Cystic Fibrosis Conference
A Double-Blind, Placebo Controlled Phase 2 Study in Adults with Cystic Fibrosis of Anabasum, A Selective Cannabinoid Receptor Type 2 Agonist, North American Cystic Fibrosis Conference
Anabasum Reduces Excessive Inflammatory Responses in Cystic Fibrosis Patient-Derived Lung Macrophages, North American Cystic Fibrosis Conference
A Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Anabasum (JBT-101) in Cystic Fibrosis (CF)
Resunab benefits in the murine model of CF lung infection and inflammation without jeopardizing resolution of Pseudomonas aeruginosa (PA) colonization in the lung, Cystic Fibrosis Foundation Research Conference
Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation, Clinical Pharmacology & Therapeutics*
Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans, American College of Rheumatology Annual Meeting
Ajulemic Acid Exerts Potent Anti-Fibrotic Effect During the Fibrogenic Phase of Bleomycin Lung, Respiratory Research*
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem 22(13):3245-3251, Bioorganic & Medicinal Chemistry*
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist, Pharma Res Per*
Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4, FASEB Journal*
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid, Rheumatology International*
CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models
58th European Association for the Study of Diabetes (EASD) presentation on CRB-913 (CB1 Inverse Agonist)
